BioSpace News Archive

Life Spine Announces First Surgical Cases of DYNA-LINK ® Titanium With Barb Fixation.

Allevion Therapeutics announced today that the Medical and Scientific Advisory Board (SAB) is expanding to include three new members — Rajesh Pahwa, M.D., Stuart H. Isaacson, M.D., and Patrick McCartney.

The projects include efficacy, safety and tolerance studies for new biomedical components, stem cell implants, dental implants, kidney transplants and the validation of latest-generation surgical robots like Bitrack, among others.

In successful conversations, people tend to adjust their language and talkativeness to reflect the behavior of the person they are speaking with.

Today, the U.S. Food and Drug Administration approved the first generic of Symbicort (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of two common pulmonary health conditions: asthma in patients six years of age and older; and the maintenance treatment of airflow obstruction and reducing exacerbations for patients with chronic obstructive pulmonary disease (COPD).

Motus GI Holdings, Inc., a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced that the Company will release its fourth quarter and full year financial results on Tuesday, March 29, 2022, after the market close.

Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies for cancer, infectious and degenerative diseases, today announced that Robert Hariri, M.D., Ph.D., Founder, Chairman and Chief Executive Officer of Celularity, and Andrew Pecora, M.D., President of Celularity, will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference.

Freeline Therapeutics Holdings plc, announced the closing of the registered direct offering of its American Depositary Shares announced on March 11, 2022.

Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three and twelve months ended December 31, 2021, and provided a corporate update.

Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2021.